HIV infection awareness and willingness to participate in future HIV vaccine trials across different risk groups in Abuja, Nigeria

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 22, Issue 10, 2010, Pages 1277-1284

  Aliyu, Gambo ^a,b   Mohammad, Mukhtar ^c   Saidu, Ahmed ^c   Mondal, Prosanta ^b   Charurat, Man ^b   Abimiku, Alash'Le ^b   Nasidi, Abdulsalami ^c   Blattner, William ^b  

^a Asokoro Hospital   (Nigeria)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c Federal Ministry of Health   (Nigeria)

Author keywords

HIV awareness; Nigeria; vaccine trials; willingness

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADULT; AWARENESS; CONDOM; CROSS-SECTIONAL STUDY; DRIVER; ETHNICITY; FEMALE; HEALTH PROMOTION; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; NIGERIA; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SEXUALITY; STUDENT;

ADOLESCENT; ADULT; AIDS VACCINES; ATTITUDE TO HEALTH; AWARENESS; CLINICAL TRIALS AS TOPIC; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NIGERIA; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT PARTICIPATION; YOUNG ADULT;

EID: 77956894869     PISSN: 09540121     EISSN: 13600451     Source Type: Journal    
DOI: 10.1080/09540121003692219     Document Type: Review

References (37)

1. Abimiku, A.G., Stern, T.L., Zwandor, A., Markham, P.D., Calef, C., Kyari, S., . . . Reitz, M.S. (1994). Subgroup G HIV type 1 isolates from Nigeria. AIDSResearch and Human Retroviruses, 10(11), 1581-1583.
2. Agwale, S.M., Zeh, C., Robbins, K.E., Odama, L., Saekhou, A., Edubio, A., . . . Kalish, M.L. (2002). Molecular surveillance ofHIV-1 field strains in Nigeria in preparation for vaccine trials. Vaccine, 20(16), 2131-2139.
3. Allen, M., Israel, H., Rybczyk, K., Pugliese, M.A., Loughran, K., Wagner, L., & Erb, S. (2001). Trialrelated discrimination in HIV vaccine clinical trials. AIDSResearch and Human Retroviruses, 17(8), 667-674.
4. Bartholow, B.N., MacQueen, K.M., Douglas Jr., J.M., Buchbinder, S., McKirnan, D., & Judson, F.N. (1997). Assessment ofthe changing willingness to participate in phase III HIV vaccine trials among men who have sex with men. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 16(2), 108-115.
5. Buchbinder, S.P., Mehrotra, D.V., Duerr, A., Fitzgerald, D.W., Mogg, R., Li, D., . . . Robertson, M.N. (2008). Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet, 372(9653), 1881-1893.
6. Celentano, D.D., Beyrer, C., Natpratan, C., Eiumtrakul, S., Sussman, L., Renzullo, P.O., . . . Nelson, K.E. (1995). Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand. AIDS, 9(9), 1079-1083.
7. Chauhan, H., Lal, P., Kumar, V., Malhotra, R., & Ingle, G.K. (2008). Awareness status about HIV/AIDS among Indian railways employees and their family members. Journal of Communicable Diseases, 40(4), 295-299.
8. Ekabua, J.E., Oyo-Ita, A.E., Ogaji, D.S., & Omuemu, V.O. (2006). KAP ofHIV prevention and screening among pregnant women attending specialist antenatal clinics in Calabar, Nigeria. Nigerian Journal of Medicine, 15(4), 409-412.
9. Halpern, S.D., Metzger, D.S., Berlin, J.A., & Ubel, P.A. (2001). Who will enroll? Predicting participation in a phase II AIDS vaccine trial. Journal of Acquired Immune Deficiency Syndromes, 27(3), 281-288.
10. Harding, A.K., Anadu, E.C., Gray, L.A., & Champeau, D.A. (1999). Nigerian university students knowledge, perceptions, and behaviours about HIV/AIDS: Are these students at risk? Journal of the Royal Society for the Promotion of Health, 119(1), 23-31.
11. Hartung, T.K., Nash, J., Ngubane, N., & Fredlund, V.G. (2002). AIDS awareness and sexual behaviour in a high HIV prevalence area in rural northern Kwazulu-Natal, South Africa. International Journal of STD & AIDS, 13(12), 829-832.
12. Howard, T.M., Olaylele, D.O., & Rasheed, S. (1994). Sequence analysis ofthe glycoprotein 120 coding region ofa new HIV type 1 subtype A strain (HIV-1IbNg) from Nigeria. AIDSResearch and Human Retroviruses, 10(12), 1755-1757.
13. Iliyasu, Z., Kabir, M., Galadanci, H.S., Abubakar, I.S., & Aliyu, M.H. (2005). Awareness and attitude ofantenatal clients towards HIV voluntary counselling and testing in Aminu Kano Teaching Hospital, Kano, Nigeria. Nigerian Journal of Medicine, 14(1), 27-32.
14. James, S., Reddy, S.P., Taylor, M., & Jinabhai, C.C. (2004). Young people, HIV/AIDS/STIs and sexuality in South Africa: The gap between awareness and behaviour. Acta Paediatrica, 93(2), 264-269.
15. Joint United Nation Program on HIV/AIDS (UNAIDS). (2008). Global AIDSepidemic released in July 2008. Retrieved from http://www.unaids.org/en/ Knowledge Centre/HIVData/GlobalReport/2008/2008-gr-mediakit.asp.
16. Kiwanuka, N., Robb, M., Kigozi, G., Birx, D., Philips, J., Wabwire-Mangen, F., . . . Gray, R.H. (2004). Knowledge about vaccines and willingness to participate in preventive HIV vaccine trials: A population-based study, Rakai, Uganda. Journal of Acquired Immune Deficiency Syndromes, 36(2), 721-725.
17. Koblin, B.A., Heagerty, P., Sheon, A., Buchbinder, S., Celum, C., Douglas, J.M., . . . Seage, G. (1998). Readiness ofhigh-risk populations in the HIV network for prevention trials to participate in HIV vaccine efficacy trials in the United States. AIDS, 12(7), 785-793.
18. Koblin, B.A., Holte, S., Lenderking, B., & Heagerty, P. (2000). Readiness for HIV vaccine trials: Changes in willingness and knowledge among high-risk populations in the HIV network for prevention trials. The HIVNET Vaccine Preparedness Study Protocol Team. Journal of Acquired Immune Deficiency Syndromes, 24(5), 451-457.
19. Lindegger, G., Quayle, M., & Ndlovu, M. (2007). Local knowledge and experiences ofvaccination: Implications for HIV-preventive vaccine trials in South Africa. Health Education & Behavior, 34(1), 108-123.
20. McCutchan, F.E., Carr, J.K., Bajani, M., Sanders-Buell, E., Harry, T.O., Stoeckli, T.C., . . . Kalish, M.L. (1999). Subtype G and multiple forms of A/G intersubtype recombinant human immunodeficiency virus type 1 in Nigeria. Virology, 254(2), 226-234.
21. McGrath, J.W., George, K., Svilar, G., Ihler, E., Mafigiri, D., Kabugo, M., & Mugisha, E. (2001). Knowledge about vaccine trials and willingness to participate in an HIV/AIDS vaccine study in the Ugandan military. Journal of Acquired Immune Deficiency Syndromes, 27(4), 381-388.
22. Moodley, K., Barnes, J., van Rensburg, E.J., & Myer, L. (2002). Willingness to participate in South African HIV vaccine trials- concerns ofmedical professionals in the Western Cape. South African Medical Journal, 92(11), 904-906.
23. Newman, P.A., Duan, N., Lee, S.J., Rudy, E., Seiden, D., Kakinami, L., & Cunningham, W. (2007). Willingness to participate in HIV vaccine trials: The impact oftrial attributes. Preventive Medicine, 44(6), 554-557.
24. OConnell, J.M., Hogg, R.S., Chan, K., Strathdee, S.A., McLean, N., Martindale, S.L., . . . Remis, R. (2002). Willingness to participate and enroll in a phase 3 preventive HIV-1 vaccine trial. Journal of Acquired Immune Deficiency Syndromes, 31(5), 521-528.
25. Onah, H.E., Mbah, A.U., Chukwuka, J.C., & Ikeme, A.C. (2004). HIV/AIDS awareness and sexual practices among undergraduates in Enugu, Nigeria. Nigerian Postgraduate Medical Journal, 11(2), 121-125.
26. Peeters, M., Esu-Williams, E., Vergne, L., Montavon, C., Mulanga-Kabeya, C., Harry, T., . . . Delaporte, E. (2000). Predominance ofsubtype A and G HIV type 1 in Nigeria, with geographical differences in their distribution. AIDSResearch and Human Retroviruses, 16(4), 315-325.
27. Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., . . . Kim, J.H. (2009). Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. New England Journal of Medicine, 361(23), 2209-2220.
28. Robb, M.L. (2008). Failure ofthe Merck HIV vaccine: An uncertain step forward. Lancet, 372(9653), 1857-1858.
29. Sahay, S., Mehendale, S., Sane, S., Brahme, R., Brown, A., Charron, K., . . . Paranjape, S. (2005). Correlates of HIV vaccine trial participation: An Indian perspective. Vaccine, 23(11), 1351-1358.
30. Sekaly, R.P. (2008). The failed HIV Merck vaccine study: A step back or a launching point for future vaccine development? Journal of Experimental Medicine, 205(1), 7-12.
31. Smit, J., Middelkoop, K., Myer, L., Seedat, S., Bekker, L.G., & Stein, D.J. (2006). Willingness to participate in HIV vaccine research in a peri-urban South African community. International Journal of STD & AIDS, 17(3), 176-179.
32. Sudha, R.T., Vijay, D.T., & Lakshmi, V. (2005). Awareness, attitudes, and beliefs of the general public towards HIV/AIDS in Hyderabad, a capital city from South India. Indian Journal of Medical Sciences, 59(7), 307-316.
33. Suhadev, M., Nyamathi, A.M., Swaminathan, S., Venkatesan, P., Raja Sakthivel, M., Shenbagavalli, R., . . . Fahey, J.L. (2006). A pilot study on willingness to participate in future preventive HIV vaccine trials. Indian Journal of Medical Research, 124(6), 631-640.
34. Thapinta, D., Jenkins, R.A., Morgan, P.A., Chiu, J., Boenim, W., Bussaratid, V., . . . Thongchareon, P. (2002). Recruiting volunteers for a multisite phase I/II HIV preventive vaccine trial in Thailand. Journal of Acquired Immune Deficiency Syndromes, 30(5), 503-513.
35. Van de Ven, P., Mao, L., Crawford, J., Prestage, G., Grulich, A., Kaldor, J., & Kippax, S. (2005). Willingness to participate in HIV vaccine trials among HIV-negative gay men in Sydney, Australia. International Journal of STD & AIDS, 16(4), 314-317.
36. Watkins, D.I., Burton, D.R., Kallas, E.G., Moore, J.P., & Koff, W.C. (2008). Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nature Medicine, 14(6), 617-621.
37. Zeh, C., Pieniazek, D., Agwale, S.M., Robbins, K.E., Odama, L., Sani-Gwarzo, N., . . . Kalish Marcia, L. (2005). Nigerian HIV type 2 subtype A and B from heterotypic HIV type 1 and HIV type 2 or monotypic HIV type 2 infections. AIDSResearch and Human Retroviruses, 21(1), 17-27.